Results 21 to 30 of about 172,248 (309)

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. [PDF]

open access: yes, 2017
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the
Aghi, MK   +14 more
core   +1 more source

A five arm natural history study of nasal vestibulitis

open access: yesCancer Medicine, 2023
Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake   +11 more
doaj   +1 more source

Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization

open access: yesVeterinary Sciences, 2023
Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to ...
Ulrike Lessiak   +3 more
doaj   +1 more source

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

open access: yes, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven   +4 more
core   +1 more source

Metformin alleviates bevacizumab-induced vascular endothelial injury in mice through growth differentiation factor 15 upregulation [PDF]

open access: yesIranian Journal of Basic Medical Sciences
Objective(s): Bevacizumab is a commonly used anticancer drug in clinical practice, but it often leads to adverse reactions such as vascular endothelial damage, hypertension, arterial and venous thrombosis, and bleeding.
Liqiang Chen   +10 more
doaj   +1 more source

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

open access: yesCancer Medicine, 2020
Introduction Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs.
Jack Patrick Gleeson   +13 more
doaj   +1 more source

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

open access: yes, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph   +7 more
core   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

open access: yesHepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai   +29 more
wiley   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

open access: yes, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta   +4 more
core   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

open access: yesHepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy